People who experience rapid eye movement sleep behaviour disorder (RBD) may go on to develop conditions such as dementia with Lewy bodies, Parkinson's disease, or multiple system atrophy. The researchers studied the medical records of 27 people with these three neurodegenerative conditions who had also experienced RBD earlier in life...

Although their genetic underpinnings differ, Alzheimer's disease, Parkinson's disease and Huntington's disease are all characterized by the untimely death of brain cells...

American neurologists and sleep experts suggest in a recent study that rapid eye movement (REM) sleep behavior disorder could be an early sign of Parkinson's disease or dementia that develops up to 50 years later. You can read how neurologist and sleep specialist Dr Bradley F...

A Glasgow-based medical research company is leading a worldwide sleep study which could radically reduce the symptoms associated with dementia. The groundbreaking trial, conducted by CPS Research, is the first of its kind to investigate the use of sleep hormone melatonin as an add on treatment for dementia. The study is already showing remarkable initial results in volunteers from Scotland...

The UK ranks 11th out of 14 countries for dementia drug use rates according to a report published by the Department of Health. The paper 'Extent and causes of international variations in drug usage' by Professor Sir Mike Richards looked at the rates of drug usage per capita for a range of diseases and drug categories in 14 countries across the world. The UK's overall ranking was eighth...

The Alzheimer's Foundation of America (AFA), New York, NY, and Second Wind Dreams (SWD), Marietta, GA, announced that they have forged a strategic partnership that will utilize their combined expertise, program strengths and local membership bases to further raise the bar on care for the increasing number of individuals nationwide with Alzheimer's disease and related dementias...

Eisai Inc. and Pfizer Inc [NYSE: PFE] announced that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept (donepezil HCl) 23 mg tablet for the treatment of moderate-to-severe Alzheimer's disease (AD). Aricept 23 mg tablet offers another dosing option for patients with moderate-to-severe AD, for whom few treatments are available...

A team of researchers from the UK and Finland has discovered why people who stay in education longer have a lower risk of developing dementia - a question that has puzzled scientists for the past decade...

The American Health Assistance Foundation (AHAF)has announced a new partnership with BioMed Central's open access journal, Molecular Neurodegeneration (MN) in which the publication will be the official open access journal of AHAF...

SIRT1, a gene associated with anti-ageing has been linked to the production of an Alzheimer's protein according to a study in Cell. Researchers at MIT found that SIRT1 appears to prevent production of damaging A-beta peptides that make up amyloid plaques which form in the brain of people with Alzheimer's...

Specialized brain training targeted at the regions of a rat's brain that process sound reversed many aspects of normal, age-related cognitive decline and improved the health of the brain cells, according to a new study from researchers at University of California, San Francisco...

More details about how the government plans to address the problem of providing care and support for an ageing population were unveiled by Secretary of State for Health, Andrew Lansley...

The Alzheimer's Association has become aware of a misleading message from the CEO of the Alzheimer's Foundation of America dated July 19, 2010. We deny and dispute all of the allegations against our Association in this letter and in AFA's lawsuit against us. We are proud of our 30 years of providing care and support to those impacted by Alzheimer's and advancing critical research...

This week at ICAD 2010, Neuronetrix for the first time publicly demonstrated their COGNISION™ System, an innovative platform which enables objective assessment of cognitive function. The demonstration focused on the COGNISION™ System's ability, using a non-invasive technology called event-related potentials (ERP), to accurately measure the cognitive performance of a patient's brain...

Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT), Head of Research, Assoc. Prof. Robert Cherny, presented new data on PBT2, the Company's lead compound in development for Alzheimer's Disease on July 14th at the prestigious International Conference of Alzheimer's Disease (ICAD) in Honolulu...

Occasional misplaced keys or forgotten names don't mark the beginning of dementia. All dementia isn't Alzheimer's disease. Some dementia symptoms can be reversed. Those facts and many more are covered in Deciphering Dementia, a supplemental Special Report to the July issue of Mayo Clinic Women's HealthSource...

The primary therapeutic target in Alzheimer's disease has been the beta amyloid peptide, which clusters outside cells in the brain to form sticky clumps known as plaques. Recently, more attention has been given to the tau protein, which aggregates inside the brain cells of people with Alzheimer's, forming neurofibrillary tangles...

Investigators have found that fruit fly (Drosophila melanogaster) males -- in which the activity of an Alzheimer's disease protein is reduced by 50 percent -- show impairments in learning and memory as they age. What's more, the researchers were able to prevent the age-related deficits by treating the flies with drugs such as lithium, or by genetic manipulations that reduced nerve-cell signaling...

Last minute scientific submissions to the Alzheimer's Association International Conference on Alzheimer's Disease 2010 (AAICAD 2010) in Honolulu, HI, known as "hot topics," suggest that (1) a newly-discovered risk gene for Alzheimer's may have early impact on memory skills and brain volume, (2) intranasal insulin may be beneficial in Alzheimer's, and (3) beta amyloid deposits i...

Janssen Alzheimer Immunotherapy, together with its collaborator on the Alzheimer's Immunotherapy Program, Pfizer, presented new research this week at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 (ICAD 2010) from two podium and four poster presentations...